EGFR mutant tumors are not very responsive to ICB therapy possibly due to their low tumor mutational burden (TMB) as compared to tumors carrying another common oncogenic driver of NSCLC, KRAS, which are more responsive to ICB (69, 70). This evidence concerns the gene KRAS and non-small cell lung carcinoma.